Affimed Therapeutics, a Heidelberg, Germany-based therapeutic TandAb antibody company, has closed a €15.5m (approximately $20m) Series D financing round.
Backers include existing investors Aeris Capital, BioMedInvest, LSP Life Sciences Partners, Novo Nordisk A/S and Orbimed.
Created as a spin-off from the German Cancer Research Centre (DKFZ), Heidelberg, and led by Dr. Adi Hoess, CEO, Affimed has generated a pipeline of drug candidates based on its proprietary TandAb(R) antibody platform.
The company intends to use the capital for clinical development of its therapeutic pipeline that consists of two TandAb products:
– AFM13, a CD30/CD16A TandAb, which is currently being evaluated in a phase I clinical trial for the treatment of Hodgkin’s Lymphoma.
– AFM11, a CD19/CD3 TandAb, which is in the late stage preclinical development and it is expected to enter phase I clinical studies in 2013.
Affimed currently employs 30 people.